Labroots

CliniMACS Prodigy® Adherent Cell Culture System: Automated, large-scale, and GMP-compliant manufacturing of various stem cells and their derivatives

Regenerative medicine has become a key focus worldwide and the number of stem cell-based clinical trials are rapidly increasing every year. Yet, large-scale and GMP-compliant stem cell manufacturing ...
Business Wire

Miltenyi Biotec Receives FDA Approval for CliniMACS® CD34 Reagent System for Prevention of Graft-Versus-Host Disease in the Treatment of Acute Myeloid Leukemia

CAMBRIDGE, Mass. & BERGISCH GLADBACH, Germany--(BUSINESS WIRE)--Miltenyi Biotec announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s CliniMACS CD34 Reagent ...
Labroots

CliniMACS Prodigy® Adherent Cell Culture System: Pluripotent stem cell expansion & differentiation in an automated, closed system

Regenerative medicine has become a key focus worldwide and the number of stem cell, especially pluripotent stem cell (PSC)-based clinical trials are rapidly increasing every year. Yet, large-scale and ...
TheHealthSite

CliniMACS Prodigy System gives cancer patient hope for un-matched bone marrow transplant

For many patients with blood cancers like leukaemia s, lymphomas & Thalassemia; Bone marrow transplantation is a life-saving therapy. Medical oncologist follows the standard blood-generating stem ...
BizTimes

Froedtert & MCW-developed cancer therapy advances to phase II clinical trial

The CliniMACS Prodigy, a device designed to manufacture cellular products used in cell-based therapies. Subscribe to BizTimes Daily – Local news about the people, companies and issues that impact ...
GEN

IsoPlexis and Miltenyi Report on Synergistic CAR-T Cell Technologies

IsoPlexis, which recently received an NCI grant, reports that it has published a technology note with Miltenyi Biotec in a co-marketing agreement. The tech note (“Getting the most out of your CAR-T ...
FierceBiotech

FDA grants humanitarian use for Miltenyi's stem cell transplant device

Miltenyi Biotec announced today that the FDA had approved its device for humanitarian use in patients with acute myeloid leukemia (AML) who are getting allogeneic stem cell transplants from matched, ...
Nature

Allogeneic bone marrow stem cell transplantation following CD34+ immunomagnetic enrichment in patients with inherited metabolic storage diseases

T-cell depletion is an essential step in reducing the risk of graft-versus-host disease (GVHD) in patients with inherited metabolic storage diseases (IMSD) undergoing hematopoietic stem cell ...
Nature

Large-scale isolation of CD133+ progenitor cells from G-CSF mobilized peripheral blood stem cells

We have evaluated the feasibility of large-scale isolation of CD133+ progenitors from healthy mobilized adult donors for potential clinical use in autologous and allogeneic transplantation. A total of ...
Europa Press

Miltenyi Biotec Receives FDA Approval for CliniMACS® CD34 Reagent System for Prevention of Graft-Versus-Host Disease in

CliniMACS(R) CD34 Reagent System approved as a Humanitarian Use Device authorized by U.S. Federal law Miltenyi Biotec announced today that the U.S. Food and Drug Administration (FDA) has approved the ...
PR Newswire

Miltenyi Biotec Receives FDA Approval for CliniMACS® CD34 Reagent System for Prevention of Graft-Versus-Host Disease in the Treatment of Acute Myeloid Leukemia

Miltenyi Biotec announced today that the U.S. Food and Drug Administration (FDA) has approved the company's CliniMACS CD34 Reagent System as a Humanitarian Use Device for the prevention of graft- ...